Sarepta Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SRPT | DSGN | CAPR | IONS | STOK | TSHA | |
|---|---|---|---|---|---|---|
| Market cap | 2.01B | 665.24M | 518.60M | 6.67B | 1.78B | 1.42B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 7.8 | -6.6 | -6.1 | -35.0 | -7.3 | -9.4 |
| Price/book | 1.3 | 3.0 | 2.1 | 15.1 | 5.0 | 3.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +7.65% | +54.73% | +32.48% | −45.82% | +22.16% | +11.22% |
| Today | +2.43% | +2.80% | +8.25% | −0.67% | +1.70% | +6.60% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SRPT news ›Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Wall Street Zen
Posted by Tristan Rich on Oct 31st, 2026 Sutro Biopharma (NASDAQ:STRO – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday, Wall…
Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms
Jul 29, 2026, 09:57 ET Funding led by Guozhong Capital will accelerate Phase 2 development for saRNA candidate RAG-01 and CNS asset RAG-17, advance systemic saRNA program RAG-18 toward IND, and expand extrahepatic RNA delivery…
Sarepta Therapeutics to Present at Upcoming Investor Conferences
HeartBeam’s Heart Attack Assessment Technology Accepted into FDA’s Total Product Life Cycle Advisory Program (TAP) Celestica Announces Third Quarter 2026 Financial Results and Will Hold 2026 Investor and Analyst Day Quantum Cyber Invited…
More from 1 other outlet
Sartorius Stedim Biotech : JP Morgan remains its Buy rating
Published on 10/22/2026 at 08:00 am EDT Sartorius Stedim Biotech: Recovery and Margin Expansion in Sight October 08, 2026 at 10:14 am EDT Option Care Health deal boosts European medical equipment makers Sartorius Stedim Biotech: finally,…
Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) and Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the…
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Rated “Reduce” by Sell-Side Analysts
Posted by Michael Walen on Oct 18th, 2026 Read Our Latest Research Report on Sarepta Therapeutics Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for…
Palisade Bio (NASDAQ:PALI) Downgraded by Wall Street Zen to “Sell”
Posted by Mitch Edgeman on Oct 18th, 2026 Wall Street Zen lowered shares of Palisade Bio (NASDAQ:PALI – Free Report) from a hold rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen reports. View Our…
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
Details from the SRP-1003 poster presentation: P-066: Preclinical Evaluation of SRP-1003: An αvβ6 Integrin-Targeting siRNA Platform for Targeted Knockdown of DMPK in Myotonic Dystrophy Type 1 (C. Greer, et al.) SRP-1003 also reduced toxic…
Enodia Therapeutics Inks Pfizer Deal to Develop Sec61-Targeting Small Molecules
Backed by multiple Sec61 inhibitor families, proteomics and cryo-EM datasets, and machine learning-driven design, Enodia Therapeutics’ platform is the foundation of a new research collaboration and license agreement with Pfizer. The post…
JMP Securities Downgrades Cortexyme to Market Perform From Market Outperform
... Biotechnology & Medical Research JMP Securities Downgrades Cortexyme to Market Perform From Market Outperform Published on 01/27/2022 at 05:40 am EST - Modified on 01/27/2022 at 05:41 am EST
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com7
- marketscreener.com4
- markets.businessinsider.com2
- theglobeandmail.com2
- tradingview.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 23 articles, not a forecast.